Artal Group’s Protagonist Therapeutics PTGX Stock Holding History

Artal Group’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-500,000	Closed	-$13.8M	–	114
2023 Q2	$13.8M	Buy	+500,000	New	+$12.5M	0.43%	35
2022 Q2	–	Sell	-800,100	Closed	-$18.9M	–	140
2022 Q1	$18.9M	Sell	800,100 -449,900	-36%	-$12.7M	0.79%	31
2021 Q4	$42.8M	Sell	1,250,000 -250,000	-17%	-$7.9M	1.16%	24
2021 Q3	$26.6M	Buy	+1,500,000	New	+$64M	0.59%	42
2021 Q2	–	Sell	-75,000	Closed	-$1.94M	–	157
2021 Q1	$1.94M	Sell	75,000 -58,000	-44%	-$1.47M	0.03%	139
2020 Q4	$2.68M	Hold	133,000	–	–	0.06%	119
2020 Q3	$2.6M	Sell	133,000 -7,000	-5%	-$131K	0.06%	117
2020 Q2	$2.47M	Buy	+140,000	New	+$1.76M	0.07%	121

Other funds holding PTGX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artal Group's PTGX Position: Q3 2023 in Review

Artal Group sold out of Protagonist Therapeutics (PTGX) in Q3 2023, closing a stake of 500,000 shares — an estimated $13.8M sold.

Artal Group first reported a position in PTGX in Q2 2020 and held it in 8 quarters. The position peaked at $42.8M in Q4 2021. 144 funds tracked by Wall St. Rank hold PTGX as of Q3 2023.

Artal Group reported no remaining Protagonist Therapeutics position as of Q3 2023 after selling out during the quarter.
Artal Group sold 500,000 Protagonist Therapeutics shares in Q3 2023, an estimated $13.8M.
Artal Group first reported a position in Protagonist Therapeutics in Q2 2020 and held it in 8 quarters.
Artal Group's Protagonist Therapeutics position peaked at $42.8M in Q4 2021.
144 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2023.

Based on Artal Group's 13F filing for Q3 2023, filed 13 Nov 2023.